Published 8 days ago • loading... • Updated 6 days ago

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

Summary by curetoday.com

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

2 Articles

All

Left

Center

Right

rarecancernews.com

Atebimetinib shows potential for advanced pancreatic cancer: Trial

Most people with advanced pancreatic cancer who received first-line treatment with atebimetinib were alive and free from disease progression six months after starting treatment, according to new data from a Phase 2 clinical trial. Among 34 evaluable patients who were given atebimetinib in addition to chemotherapy, 94% were alive and 72% were free from disease progression at six months. Historical data indicate 67% of pancreatic patients live for…

6 days ago

Read Full Article

curetoday.com

Atebimetinib Combo Shows 94% 6-Month Survival in Pancreatic Cancer

Atebimetinib with modified chemo led to 94% 6-month survival rates in first-line pancreatic cancer, with durable responses and a favorable safety profile.

8 days ago

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year

Stories disproportionately reported by the Left or the Right